Page last updated: 2024-12-10

iododiflunisal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

iododiflunisal: an amyloid inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4369563
CHEMBL ID1232738
SCHEMBL ID5380998
MeSH IDM0490911

Synonyms (11)

Synonym
CHEMBL1232738 ,
FHI ,
2',4'-difluoro-4-hydroxy-5-iodo-1,1'-biphenyl-3-carboxylic acid
iododiflunisal
5-(2,4-difluorophenyl)-2-hydroxy-3-iodobenzoic acid
SSYOLLIRAAWGDJ-UHFFFAOYSA-N
5-(2,4-difluorophenyl)-3-iodo-salicylic acid
SCHEMBL5380998
2',4'-difluoro-4-hydroxy-5-iodobiphenyl-3-carboxylic acid
Q27460296
bdbm50527390
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TransthyretinHomo sapiens (human)Kd0.56500.00301.348210.0000AID1605601; AID1605604
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1322960Displacement of [125I]-T4 from wild type TTR in human plasma after 1 hr by PAGE analysis2016European journal of medicinal chemistry, Oct-04, Volume: 121A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
AID1605602Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) Star assessed as improvement in dissociation constant for TTR-amyloid beta (1 to 42) complex formation at 200 uM at 25 degC pre-incubated with transthyretin before amyl
AID1605605Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) Star assessed as reduction in fibril formation by measuring round particles and pre-fibrillar species levels at 50 uM pre-incubated with transthyretin for 1 hr before a
AID1605603Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) Star assessed as fibril formation at 50 uM pre-incubated with transthyretin before amyloid beta (1 to 42) addition by ThT fluorescence assay (Rvb = 25 +/- 1%)
AID1898636Binding affinity to wild type TTR/Amyloid beta (1 to 40 residues) binary complex (unknown origin) assessed as complex dissociation constant by isothermal titration calorimetry2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID1322965Stabilization of TTR V30M mutant tetramer in human plasma assessed as tetramer to total protein ratio preincubated overnight at 4 degC followed by further incubation at room temperature for 1 hr in presence of 4M urea by isoelectric focusing densitometric2016European journal of medicinal chemistry, Oct-04, Volume: 121A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
AID1054847Inhibition of human recombinant TTR Y78F mutant-mediated fibrillogenesis at 40 uM after 30 mins by turbidimetric assay relative to control2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID1898638Binding affinity to wild type TTR/Amyloid beta (1 to 40 residues) binary complex (unknown origin) assessed as change in enthalpy binary by isothermal titration calorimetry2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID1322953Stabilization of wild type TTR tetramer in human plasma assessed as tetramer to total protein ratio preincubated overnight at 4 degC followed by further incubation at room temperature for 1 hr in presence of 4M urea by isoelectric focusing densitometric a2016European journal of medicinal chemistry, Oct-04, Volume: 121A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition.
AID1898640Neuroprotective activity against amyloid beta (1 to 42 residues)-induced cell injury in human SH-SY5Y cells assessed as reduction in caspase 3 level2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID1898639Binding affinity to wild type TTR/Amyloid beta (1 to 40 residues) binary complex (unknown origin) assessed as change in entropy for binary complex by isothermal titration calorimetry2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID1898641Inhibition of amyloid beta (1 to 42) (unknown origin) self aggregation after 24 hrs by thioflavin-T fluorescence method2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID1054846Binding affinity to human recombinant TTR Y78F mutant after 5 mins by isothermal titration calorimetry2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID1054848Inhibition of human recombinant TTR Y78F mutant-mediated fibrillogenesis after 30 mins by turbidimetric assay2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Modulation of the fibrillogenesis inhibition properties of two transthyretin ligands by halogenation.
AID1605604Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) Star assessed as dissociation constant for TTR-amyloid beta (12 to 28) complex formation at 200 uM at 25 degC pre-incubated with transthyretin before amyloid beta (12 t
AID1898637Binding affinity to wild type TTR/Amyloid beta (1 to 40 residues) binary complex (unknown origin) assessed as Gibbs free energy change for binary complex by isothermal titration calorimetry2021European journal of medicinal chemistry, Dec-15, Volume: 226Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease.
AID1605601Stabilization of wild type human transthyretin expressed in Escherichia coli BL21(DE3) Star assessed as dissociation constant for TTR-amyloid beta (1 to 42) complex formation at 200 uM at 25 degC pre-incubated with transthyretin before amyloid beta (1 to
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (7.14)29.6817
2010's8 (57.14)24.3611
2020's5 (35.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]